Increased expression of miR‐641 contributes to erlotinib resistance in non‐small‐cell lung cancer cells by targeting NF1

Epidermal growth receptor (EGFR)‐targeted tyrosine kinase inhibitors (TKIs) have emerged as first‐line drugs for advanced non‐small‐cell lung cancer (NSCLC) patients with EFGR mutations. However, most patients with NSCLC show acquired resistance to EGFR‐TKIs, and low expression of NF1 is a mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Juan, Cui, Jie‐da, Guo, Xiao‐tong, Cao, Xia, Li, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911582/
https://www.ncbi.nlm.nih.gov/pubmed/29493886
http://dx.doi.org/10.1002/cam4.1326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911582/
https://www.ncbi.nlm.nih.gov/pubmed/29493886
http://dx.doi.org/10.1002/cam4.1326

Ejemplares similares